Vivos Therapeutics Inc.

VVOS | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.50

-$0.01 (-2.19%)

Jun 18, 2026, 4:00 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.19%

(1D)

Rating

Updated: May 9, 2026

Fundamentals Weak

Market Sentiment Bearish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $2.94M

1D Range

0.45 0.52

52W Range

0.45 7.95

Valuation (TTM)

PE -0.22

PB -2.59

EV/EBITDA -0.57

Valuation (NTM)

Forward PE N/A

Forward PEG N/A

Price Target $2.13

Cash Flow

FCF Yield -619.7%

SBC Adj. FCF Yield -636.5%

SBC Impact -2.7%

Margins

Gross Margin 59.5%

Operating Margin -113.2%

FCF Margin -93.3%

Growth (CAGR)

Revenue 3Y | 5Y 2.9% | 6.0%

Dil EPS 3Y | 5Y 30.7% | 18.3%

FCF 3Y | 5Y 4.7% | -40.7%

Returns

ROA -100.3%

ROE -2239.2%

ROIC -148.6%

Financial Health

Net Debt

$9.74M

Current Ratio 0.27

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in ad...

Sector Healthcare

Industry Medical - Devices

Employees 109

IPO Date Dec 10, 2020

Website vivos.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Latest Earnings

May 20, 2026

EPS

-$0.52

Miss -15.56%

YoY: -15.56%

REV

$5.14M

Beat +18.22%

YoY: +70.46%

Next Earnings

Aug 18, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞